
iCAD
Breast screening AI for lesion detection and density risk

Tool details
iCAD is a US breast-AI screening vendor acquired by RadNet's DeepHealth subsidiary in 2025. Its ProFound suite runs lesion detection, breast density and an image-based risk model as one pipeline, plugged straight into the radiologist's reading workflow.
Core capabilities
- Detection V4: concurrent reading that marks masses, architectural distortion and calcification clusters on 2D and 3D tomosynthesis, scoring every lesion and the exam as a whole with a Case Score
- Prior comparison: folds prior mammograms into the analysis and cross-checks ipsilateral CC and MLO views to cut duplicate marks
- Density assessment: PowerLook returns a breast density category automatically instead of eyeballing it, feeding supplemental-screening decisions
- Image-based risk model: ProFound AI Risk predicts future cancer risk from imaging features; the vendor claims 2.4x the accuracy of traditional models
- Deployment flexibility: on-premises, Docker and cloud, reading from Hologic workstations or third-party PACS
Where it fits Breast screening centres, imaging chains and third-party reading groups feel it first: high volume, costly false-positive recalls, and a second read that saves both time and recalls. Device makers can license it for embedded integration as well.
What sets it apart A training set of 20M+ images, 88,000 cases and 13,500 biopsy-confirmed cancers from 130 contributing centres is the hardest barrier here; detection, density and risk share one imaging foundation, so a buyer can sign once. Detection holds FDA 510(k), CE and Health Canada clearances.
Editorial take The clinical evidence and regulatory standing hold up, which puts it in the category that can clear hospital procurement. Two caveats: the risk model carries only CE and Health Canada, not FDA clearance, and is investigational in the US; and there is no public pricing, so the whole path runs through a sales demo.
Pricing
Custom pricingCustom (quote only)Licensed by institution size and modules, subject to sales review
Additional notes
No public price page; procurement runs through Request a Demo
FAQ
User reviews
User Reviews
No reviews yet
No one has reviewed this tool yet